Interleukin-2 biosimilar - Laboratorio Varifarma
Alternative Names: Ilcass; Interleukina-2 recombinanteLatest Information Update: 28 Oct 2021
At a glance
- Originator Laboratorio Varifarma
- Developer Laboratorio Pablo Cassara; Laboratorio Varifarma
- Class Adjuvants; Antineoplastics; Immunotherapies; Interleukins; Lymphokines
- Mechanism of Action Immunostimulants; Interleukin 2 receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Cancer
Most Recent Events
- 10 Aug 2011 Launched for Cancer in Argentina (Parenteral)